Display options
Cite
Thibaut de Ménonville S, Rosignoli C, Soares E, et al. Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models. Dermatol Ther (Heidelb). 2017;7(2):213-225doi: 10.1007/s13555-017-0176-3.
Thibaut de Ménonville, S., Rosignoli, C., Soares, E., Roquet, M., Bertino, B., Chappuis, J. P., Defoin-Platel/Chaussade, C., & Piwnica, D. (2017). Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models. Dermatology and therapy, 7(2), 213-225. https://doi.org/10.1007/s13555-017-0176-3
Thibaut de Ménonville, Séverine, et al. "Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models." Dermatology and therapy vol. 7,2 (2017): 213-225. doi: https://doi.org/10.1007/s13555-017-0176-3
Thibaut de Ménonville S, Rosignoli C, Soares E, Roquet M, Bertino B, Chappuis JP, Defoin-Platel/Chaussade C, Piwnica D. Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models. Dermatol Ther (Heidelb). 2017 Jun;7(2):213-225. doi: 10.1007/s13555-017-0176-3. Epub 2017 Feb 27. PMID: 28243927; PMCID: PMC5453918.
Copy Download .nbib Format: NLM
Share it on

Dermatol Ther (Heidelb). 2017 Jun;7(2):213-225. doi: 10.1007/s13555-017-0176-3. Epub 2017 Feb 27.

Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.

Dermatology and therapy

Séverine Thibaut de Ménonville, Carine Rosignoli, Estelle Soares, Manon Roquet, Béatrice Bertino, Jean-Paul Chappuis, Claire Defoin-Platel/Chaussade, David Piwnica

Affiliations

  1. Nestlé Skin Health R&D, Sophia Antipolis, France. [email protected].
  2. Nestlé Skin Health R&D, Sophia Antipolis, France.

PMID: 28243927 PMCID: PMC5453918 DOI: 10.1007/s13555-017-0176-3

Abstract

INTRODUCTION: Numerous intrinsic and extrinsic factors have been associated with the pathophysiology of rosacea, including dysregulation of innate immunity. A high level of cathelicidin antimicrobial peptides (e.g., LL-37) has been shown in the facial skin of patients with rosacea. Excessive production of both LL-37 and KLK5, the serine protease responsible for its cleavage, has been suggested to play a role in the pathophysiology of rosacea. Ivermectin 10 mg/g cream, indicated for the treatment of inflammatory lesions of rosacea, is reported to have dual anti-parasitic and anti-inflammatory properties. However, the exact mechanism of action of ivermectin cream in the treatment of rosacea is unknown.

METHODS: This study aimed to evaluate the effect of ivermectin on the expression of KLK5 and the subsequent effect on the maturation process of cathelicidins. Experimental studies were performed either on normal human epidermal keratinocytes (NHEK), reconstructed human epidermis (RHE) or on human skin ex vivo stimulated with calcitriol (1α,25-dihydroxyvitamin D3), which is known to induce KLK5 and LL-37 expression.

RESULTS: The results show that ivermectin is able to inhibit KLK5 and CAMP gene expression and protein secretion in NHEK cells stimulated with calcitriol. Those results were confirmed in 3D models of the skin (RHE and skin ex vivo). The anti-inflammatory effects of ivermectin were associated with an inhibition of IL-8, IL-6 and MCP-1 (CCL2) secretion from NHEK cells.

CONCLUSIONS: These results suggest that ivermectin can prevent the inflammatory effects of rosacea triggered by abnormal LL-37 processing, through the inhibition of KLK5 gene expression in the epidermis.

FUNDING: Nestlé Skin Health R&D.

Keywords: Cathelicidin; Innate immunity; Ivermectin; Rosacea

References

  1. J Leukoc Biol. 2002 Nov;72(5):847-55 - PubMed
  2. J Clin Invest. 2003 Jun;111(11):1665-72 - PubMed
  3. J Invest Dermatol. 2007 Mar;127(3):594-604 - PubMed
  4. Immunol Cell Biol. 1999 Dec;77(6):469-75 - PubMed
  5. J Invest Dermatol. 2012 May;132(5):1435-42 - PubMed
  6. J Am Acad Dermatol. 2016 Jun;74(6):1086-92 - PubMed
  7. J Investig Dermatol Symp Proc. 2011 Dec;15(1):53-62 - PubMed
  8. J Invest Dermatol. 2011 Mar;131(3):688-97 - PubMed
  9. Inflamm Res. 2011 Jun;60(6):589-96 - PubMed
  10. FASEB J. 2006 Oct;20(12):2068-80 - PubMed
  11. Cell. 1975 Nov;6(3):317-30 - PubMed
  12. J Am Acad Dermatol. 2013 Oct;69(4):570-7 - PubMed
  13. J Invest Dermatol. 2010 May;130(5):1297-306 - PubMed
  14. J Dermatolog Treat. 2015;26(4):379-80 - PubMed
  15. J Investig Dermatol Symp Proc. 2011 Dec;15(1):2-11 - PubMed
  16. J Clin Aesthet Dermatol. 2014 Jan;7(1):20-5 - PubMed
  17. Inflamm Res. 2008 Nov;57(11):524-9 - PubMed
  18. J Drugs Dermatol. 2012 Jun;11(6):694-700 - PubMed
  19. J Drugs Dermatol. 2014 Nov;13(11):1380-6 - PubMed
  20. Cell. 1975 Nov;6(3):331-43 - PubMed
  21. J Investig Dermatol Symp Proc. 2011 Dec;15(1):12-5 - PubMed
  22. J Eur Acad Dermatol Venereol. 2016 May;30(5):829-36 - PubMed
  23. Ann Chir Plast. 1979;24(4):357-62 - PubMed
  24. Exp Dermatol. 2014 Jun;23(6):379-81 - PubMed
  25. J Exp Med. 2000 Oct 2;192(7):1069-74 - PubMed
  26. J Am Acad Dermatol. 2004 Sep;51(3):327-41; quiz 342-4 - PubMed
  27. J Investig Dermatol Symp Proc. 2011 Dec;15(1):16-23 - PubMed
  28. Nat Med. 2007 Aug;13(8):975-80 - PubMed

Publication Types